CoChat

Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index; none of the 33 sources its claims cite is checked for support yet.

Abstract

BACKGROUND: Malaria is a complex disease, which varies in its epidemiology and clinical manifestation. Although artemether-lumefantrine has been used as first-line drug for uncomplicated Plasmodium falciparum malaria in Bahir Dar district since 2004, its efficacy has not yet been assessed. The main objective of this study was to quantify the proportion of patients with uncomplicated falciparum malaria who were prescribed artemether-lumefantrine and who failed treatment after a 28-day follow-up. METHODS: The research team attempted to conduct an observational cohort study on the assessment of therapeutic efficacy and safety of artemether-lumefantrine in falciparum malaria patients aged over five years in Bahir Dar district from March to July 2012. RESULTS: Among 130 participants in the study, 60% were males with 1:5 male to female ratio. The mean of asexual parasitaemia load was 8675 parasites/μL and 96.1% participants were free from parasitaemia at day 3. At the end of the study, 98.5% of participants showed adequate clinical and parasitological response of the drug. In the study, only 1.5% of participants were shown late parasitological failure between seventh and 14th day follow-up and 1.3% of participants were free from anaemia at the end of follow-up. CONCLUSION: According to the research findings, artemether-lumefantrine fulfilled the inclusion criteria of WHO as first-line drug and continues to be the drug of choice for the treatment of uncomplicated falciparum malaria. Outputs from this study should be supported through advanced molecular techniques and blood concentration and pharmaco-vigilance of the drug.

Overview

CoChat Summary

TL;DR

In a 28-day observational cohort in Bahir Dar district, Northwest Ethiopia, artemether-lumefantrine achieved a 98.5% adequate clinical and parasitological response among 130 patients with uncomplicated *Plasmodium falciparum* malaria. The drug was well tolerated, with no severe adverse effects beyond FDA-registered events, though the authors call for molecular and pharmacovigilance follow-up.

Key findings

  • At day 28, 98.5% of participants showed adequate clinical and parasitological response (abstract; Table 2 reports 128/130, 98.4%); late parasitological failure occurred in 1.5% (2/130) between day 7 and day 14, with no early or late clinical failure reported.
  • Mean asexual parasitaemia at day 0 was 8675 parasites/μL; 85.9% and 96.1% of participants were parasite-free at days 2 and 3, respectively, and gametocytes cleared by day 7.
  • Mean haemoglobin increased from 10.82 g/dl at day 0 to 11.21 g/dl at day 28; 1.3% of anaemic participants became non-anaemic (≥11 g/dl).
  • 32% of participants reported common/typical adverse effects; the most frequent were weakness/fatigue and headache (15.9%), mouth rash (14.7%), and cough (11.5%), with no severe adverse effects recorded beyond FDA-registered events.

Methods

  • A 28-day observational cohort study conducted according to the 2009 WHO protocol in Bahir Dar district from March to July 2012; 778 febrile cases were screened, 134 *P. falciparum* mono-infected patients were eligible, and 130 completed follow-up.
  • Eligibility included age ≥5 years, parasite density 1000–100,000 parasites/μL, no severe/complicated malaria, no prior antimalarial use, and consent; participants received six supervised doses of AL (20 mg artemether/120 mg lumefantrine) and were followed on days 3, 7, 14, 21, and 28.
  • Laboratory assessment used thick/thin Giemsa-stained blood films with parasite counts per 200 leukocytes ×40 and haemoglobin by packed cell volume; analysis used EPI 2002 and SPSS 16 with frequency, chi-square, and logistic regression at α = 0.05.

Limitations

  • The paper has no formal limitations section; the conclusion states that outputs should be supported by advanced molecular techniques, blood concentration measurement, pharmacovigilance, and further PCR-based effectiveness studies.
  • Evident from the text: single-district observational cohort with 130 completers, no comparator arm, no molecular genotyping to distinguish recrudescence from reinfection, and no drug-level measurement.
  • The text also shows minor internal inconsistencies in reported efficacy (98.5% in the abstract, 98.4% in Table 2, 98.3% in the discussion) and in the stated sex ratio.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12936-015-0744-x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Details on study inclusion and follow up progress Bahir Dar district, March to July 2012. Among 778 malaria suspected and screened individuals, 134 P.f. mono-infected participants considered as eligible study subjects. Of them, 4 individuals excluded from the study and 130 study participants finished and drug efficacy and safety outcomes were drawn
Fig. 1 Details on study inclusion and follow up progress Bahir Dar district, March to July 2012. Among 778 malaria suspected and screened individuals, 134 P.f. mono-infected participants considered as eligible study subjects. Of them, 4 individuals excluded from the study and 130 study participants finished and drug efficacy and safety outcomes were drawnCC BY · PubMed Central
Fig. 2 Demographic characters of study subjects within 28 days of follow-up, Bahir Dar district, March to July 2012. A total of 130 eligible participants, 78 (60 %) males with 1:5 male to female ratio. The majority of study subjects (32.33 %) were in age group five to 14 years and males were in the majority in the age groups
Fig. 2 Demographic characters of study subjects within 28 days of follow-up, Bahir Dar district, March to July 2012. A total of 130 eligible participants, 78 (60 %) males with 1:5 male to female ratio. The majority of study subjects (32.33 %) were in age group five to 14 years and males were in the majority in the age groupsCC BY · PubMed Central
Fig. 3 Summary of fever and parasitic load clearances within 28 days of follow-up, Bahir Dar district, March to July 2012. The study tried to correlate the overall febrile case reduction with the geometric mean of parasitic clearance at days 0 and 3. Fever clearance rate was insignificantly associated with parasitic clearance (P = 0.054, 95 % CI)
Fig. 3 Summary of fever and parasitic load clearances within 28 days of follow-up, Bahir Dar district, March to July 2012. The study tried to correlate the overall febrile case reduction with the geometric mean of parasitic clearance at days 0 and 3. Fever clearance rate was insignificantly associated with parasitic clearance (P = 0.054, 95 % CI)CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 1 Not valid · 13 Not checked · 28 Own results and interpretations

13 more claims

Create a free account to see all 42 claims and to verify the 33 references still open.

See all claims — free account
  • It may state two separate claims as one. 17
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Africa-focused bulletins on malaria. Dramatic anti-malarial results. 2008. http://www.africafocus.org/country/zambia.php .

Cited by

See all 24

Metadata

Authors
Ebstie, Y. A., Zeynudin, A., Belachew, T., Desalegn, Z., & Suleman, S.
Affiliations
  • Addis Ababa University (ET)
  • Jimma University (ET)
Corresponding author
Ebstie, Yehenew A.
Venue
Malaria Journal
Published
2015-06-05
Volume
14
Issue
1
Pages
236-236
ISSN
1475-2875 (ISSN-L)
OpenAlex
W1552753591
Cited by
24
References
23
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 4
FWCI
2.14
Type
journal article
Language
en
Open access
Locations
  • Malaria Journal (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Greater South Information System
Funders
Jimma University (Grant code:ID0EZPAE404)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
Keywords
artemether-lumefantrine, falciparum malaria, uncomplicated malaria, antimalarial drug efficacy, treatment failure, parasitological response, anemia, drug safety
MeSH terms
Artemether, Lumefantrine Drug Combination, Adolescent, Adult, Aged, Antimalarials, Child, Child, Preschool, Drug Combinations, Ethanolamines, Ethiopia, Female, Fluorenes, Humans, Male, Middle Aged, Plasmodium falciparum, Cohort Studies, Malaria, Falciparum, Treatment Outcome, Parasitemia, Artemisinins, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study. https://app.cochat.ai/papers/10.1186/s12936-015-0744-x
The paper
Ebstie, Y. A., Zeynudin, A., Belachew, T., Desalegn, Z., & Suleman, S. (2015). Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study. Malaria Journal. https://doi.org/10.1186/s12936-015-0744-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.